Summary
This is a clinical oncology trial report documenting extended follow-up (≥2 years) from the phase III JAVELIN Bladder 100 trial, which compared avelumab first-line maintenance immunotherapy plus best supportive care against BSC alone in patients with advanced urothelial carcinoma who had not progressed after platinum-containing chemotherapy. The updated analysis confirms that avelumab maintenance therapy provides a clinically meaningful and sustained overall survival benefit (hazard ratio 0.76), with consistent safety and no new adverse signals emerging with longer treatment duration. This work is outside the scope of Vitagri's Pulse Brain catalogue, which focuses on farming systems, soil health, nutrient density, and food-related aspects of human health.
UK applicability
This trial's findings on immunotherapy efficacy and safety are applicable to UK oncology practice and may inform UK National Cancer Research Institute guidance and NHS commissioning of avelumab for eligible patients with advanced urothelial carcinoma. However, the paper does not address farming, soil health, or nutritional aspects relevant to Vitagri's scope.
Key measures
Overall survival (hazard ratio 0.76, 95% CI 0.63–0.91, P=0.0036); progression-free survival; adverse events; treatment duration (≥2 years in 19.5% of avelumab patients); median follow-up 38.0–39.6 months
Outcomes reported
The study reported overall survival (OS), progression-free survival (PFS), safety outcomes, and additional novel analyses in patients with advanced urothelial carcinoma receiving avelumab first-line maintenance plus best supportive care versus BSC alone, with ≥2 years of follow-up data.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.